Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.
US HUPO 2025
Loews Philadelphia Hotel 1200 Market St, Philadelphia, PA, United StatesJoin the Poster Sessions Poster Session 1: Monday, February 24th (P08.03) Considerations for Large Cohort Exploratory Studies: Proof-of-Concept Using Stage-IV Oncology Plasma from 500 Donors Presented by: Danielle Gutierrez, Ph.D […]